Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Actuate Therapeutics IncNASDAQ: ACTU
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 98.8% from a year ago
Total assets stood at $8.91M at the end of Q1 FY2026, up 98.8% from a year earlier and down 36.5% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +98.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 14.04M USD
- Year-over-year change
- +50.6%
- 3-year CAGR
- -11.8%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.04M | +50.6% |
| FY2024 | 2024-12-31 | 9.32M | +211.1% |
| FY2023 | 2023-12-31 | 3M | -85.4% |
| FY2022 | 2022-12-31 | 20.48M | — |
Total Assets vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +98.8% is the 2nd highest of 9, against a peer median of -22.5%.
- Over three fiscal years its annual growth of -11.8% compares with a peer median of -12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $506.75M USD | +363.6% | +15.7% | |
| Mar 2026 | $372.07M USD | -20.9% | -5.1% | |
| Mar 2026 | $239.92M USD | -41.2% | -28.1% | |
| Mar 2026 | $156.3M USD | +22.7% | -7.2% | |
| Mar 2026 | $117.62M USD | -28.4% | -26.6% | |
| Mar 2026 | CHF 87.4M CHF | -38.1% | -27.0% | |
| Mar 2026 | $59.02M USD | -24.0% | -18.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $22.69M USD | -19.4% | +4.5% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.91M USD | +98.8% | -11.8% |
| Peer median (excluding ACTU) | — | -22.5% | -12.6% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.